Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 118

Results For "CARE"

4011 News Found

AstraZeneca’s Phase III FLAURA2 trial shows positive result
News | September 15, 2025

AstraZeneca’s Phase III FLAURA2 trial shows positive result

Tagrisso plus chemotherapy achieves nearly four-year median overall survival in EGFR-mutated advanced lung cancer, setting new global standard in phase III trial


Yatharth Hospitals acquires Shantived Hospital in Agra for Rs. 260 Cr
Healthcare | September 14, 2025

Yatharth Hospitals acquires Shantived Hospital in Agra for Rs. 260 Cr

Shantived Hospital generated revenue of around Rs 50 crore in FY2025


Apollo Hospitals acquires IFC’s 3% share in Apollo Health and Lifestyle for Rs. 1,254 Cr
News | September 13, 2025

Apollo Hospitals acquires IFC’s 3% share in Apollo Health and Lifestyle for Rs. 1,254 Cr

AHLL will become a 100% subsidiary of AHEL with 99.42% held by AHEL and balance in the ESOP pool


Shukra Pharmaceuticals inks distribution tie-up with Wockhardt
Supply Chain | September 12, 2025

Shukra Pharmaceuticals inks distribution tie-up with Wockhardt

The products include high-quality, advanced anti-infective formulations such as EMROK (Levonadifloxacin) and MIQNAF (Nafithromycin)


VedaBio to use Mammoth Biosciences’ CRISPR-based technology for diagnostic applications
News | September 12, 2025

VedaBio to use Mammoth Biosciences’ CRISPR-based technology for diagnostic applications

CRISPR-based detection enables highly specific molecular recognition


A.forall expands US generics portfolio
News | September 12, 2025

A.forall expands US generics portfolio

Four FDA-approved products strengthen portfolio and reaffirm commitment to global reach


Lonza appoints Jason Berndt as Head of Group Operations
People | September 12, 2025

Lonza appoints Jason Berndt as Head of Group Operations

Maria Soler Nunez appointed as Chief Quality Officer


Novartis to acquire Tourmaline Bio for $1.4 billion
News | September 10, 2025

Novartis to acquire Tourmaline Bio for $1.4 billion

Tourmaline Bio is a clinical-stage biopharmaceutical company developing pacibekitug, an anti-IL-6 mAb, as a treatment option for atherosclerotic cardiovascular disease